Integrated BioPharma (OTCMKTS:INBP – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $9.91 million for the quarter. Integrated BioPharma had a negative return on equity of 14.78% and a negative net margin of 6.48%.
Integrated BioPharma Stock Performance
Integrated BioPharma stock remained flat at $0.17 during mid-day trading on Friday. Integrated BioPharma has a 12 month low of $0.14 and a 12 month high of $0.42. The company has a market capitalization of $5.12 million, a P/E ratio of -1.65 and a beta of 0.49. The business’s fifty day simple moving average is $0.17 and its 200 day simple moving average is $0.22.
Integrated BioPharma Company Profile
Integrated BioPharma, Inc. is a healthcare and consumer-products company that manufactures, distributes and markets vitamins, nutritional supplements, herbal products and specialty pharmaceutical products. Its activities include producing health and wellness products for its own brands as well as providing contract manufacturing services for other businesses. The company’s product offerings have included dietary supplements, botanical and herbal formulations, vitamins, minerals and other nutrition-related products.
Featured Stories
- Five stocks we like better than Integrated BioPharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
